Yale Cancer Center Physicians Bring Myeloma Message to Hamden’s Newhall Neighborhood
Doctors and researchers still are not sure what causes myeloma, a rare cancer of the white blood cells that initially shows few symptoms, but they do know that 20 percent of myeloma cases are detected in Black Americans – and that the number is rising. That is why members of the Yale Myeloma team went to Hamden’s Newhall neighborhood on November 30 for, “Understanding Myeloma: A Community Event.”
Phase 3 Results Offer Hope for Patients With Myelodysplastic Syndromes
Senior author of the study and Yale Cancer Center expert Amer Zeidan , MBBS, says the results showed that imetelstat, a first-in-class telomerase inhibitor, leads to durable red blood cell transfusion independence and a significant improvement in anemia in heavily transfused lower-risk MDS patients.
Lung-MAP Shows Potential of Public-Private Partnerships
The unique public-private partnership that for almost a decade has undergirded the first National Cancer Institute (NCI)-sponsored precision medicine clinical trial in lung cancer can serve as a model for future clinical research that is more rapid, innovative, and inclusive.Source: SWOG
Yale Cancer Center Experts Present New Research at Hematology Annual Meeting
Physicians and scientists from Yale Cancer Center, part of Yale School of Medicine, will present new research at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, Calif., from December 9 to 12.
Health Headlines: New lung cancer screening guidelines
In today’s health headlines, we discuss the benefits of the new lung cancer screening guidelines, an update on small cell lung cancer treatment and the importance of clinical trials. Dr. Anne Chiang, associate professor at Yale School of Medicine and associate director for clinical initiatives at Yale Cancer Center and Smilow Cancer Hospital, joined News 8 to discuss these topics.Source: WTNH
Dr. George Goshua Named Finalist for NOMIS & Science Young Explorer Award
In recognition of his innovation and visionary research, George Goshua, MD, MSc, Assistant Professor of Medicine (Hematology), has been recognized as a finalist for the NOMIS & Science Young Explorer Award. The award acknowledges three young and creative researchers across the globe who take bold risks to ask fundamental questions at the intersection of life and social sciences and who have made significant advances in applying techniques developed in one domain to address questions in another.
CT ranks second in early lung cancer diagnosis, but stark racial disparities persist, report finds
Connecticut ranks second nationwide for early diagnosis and five-year survival of lung cancer, but sharp disparities persist in early detection and treatment for Black, Latino, and Pacific Islander populations. That’s according to new data released Tuesday by the American Lung Association. The report found Connecticut’s overall lung cancer survival rates across all ethnic groups are higher than the national average. Connecticut also ranked second nationally in early diagnosis of lung cancer. But Dr. Roy Herbst, deputy director of Yale Cancer Center said, “the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.”Source: CT Public
Yale Biomedical Engineers Develop Nanoparticle Brain Cancer Treatment
In a recent study, Yale researchers developed a new way to more effectively treat brain cancer using nanoparticles. Led by biomedical engineering professor Mark Saltzman and radiology professor Ranjit Bindra, the team first administered mice with medulloblastoma, a brain cancer that predominantly affects children. Then, they developed and used drug-carrying nanoparticles to deliver treatment over a sustained period of time. The study showed that mice who received this treatment lived significantly longer than mice who received traditional brain cancer treatment. “This treatment is a way to directly target tumor cells in the central nervous system (CNS) with the potential to minimize toxic therapies, like radiation therapy to the CNS, as well as high doses of systemically administered chemotherapies,” Bindra told the News.Source: Yale Daily News
YHN SPORE collaborators Receive $13.3 Million Renewal of Grant to Address Cancer Health Disparities
YHN SPORE collaborators at FCCC have received a five-year, $13.3 million competitive grant renewal from the National Cancer Institute (NCI), part of the National Institutes of Health, to address cancer health disparities.Source: Fox Chase
Nanoparticles Deliver Treatment Directly to Tumors of Deadly Brain Cancer
Using nanoparticles administered directly into the cerebrospinal fluid (CSF), a research team has developed a treatment that may overcome significant challenges in treating a particularly deadly brain cancer. The researchers, led by professors Mark Saltzman, PhD, and Ranjit Bindra, MD, PhD, administered to mice with medulloblastoma a treatment that features specially designed drug-carrying nanoparticles. The study, published in Science Translational Medicine, showed that mice who received this treatment lived significantly longer than mice in the control group.
The Exciting Potential of Antibody-Drug Conjugates in Lung Cancer
MedPage Today brought together three expert leaders for a virtual roundtable discussion on lung cancer: Moderator Roy Herbst, MD, PhDopens in a new tab or window, was joined by Anne Chiang, MD, PhDopens in a new tab or window, and So Yeon Kim, MDopens in a new tab or window, all from the Yale Cancer Center in New Haven, Connecticut. This final of four exclusive episodes looks at the exciting ongoing development of antibody-drug conjugates (ADCs) in non-small cell lung cancer (NSCLC). You can see other videos in this series hereopens in a new tab or window.Source: MedPage Today
Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options
Advances in non-small cell lung cancer (NSCLC) will take center stage at the European Society for Medical Oncology (ESMO) Congress 2023 happening Friday through Tuesday in Madrid, Spain. Seven of the 15 late-breaking abstracts to be presented during the three presidential sessions focus on NSCLC. “It’s a very fertile time in lung cancer, with many new drugs and much under study. [I am] looking forward to the meeting,” said Roy S. Herbst, MD, PhD, deputy director of Yale Cancer Center and chief of medical oncology for Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut.Source: OBR Oncology